We cant wait to hear from you
With the advantages of convenient oral administration and precise dosing, the product have become commonly used preparations in animal anti-aging research, focusing on the following areas
April 2026 Category 2 Update On April 15, 2026, the FDA confirmed removal of injectable GHK-Cu from Category 2 because the original nominations were withdrawn
Preclinical safety evaluation of body protective compound-157, a potential drug for treating various wounds
Holt, attorney and owner of Holt Law, a health-care business law firm in Minnesota and California, points out that it was moved to Category 2 in 2023, so legally, compounding pharmacies cannot distribute it for human use. But theyre using that for research purposes loophole to distribute it